ELIQUIS Receives FDA Approval in Reducing Certain Risks in Nonvalvular Atrial Fibrillation
Go back to ELIQUIS Receives FDA Approval in Reducing Certain Risks in Nonvalvular Atrial Fibrillation| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 67.61 +1.56 (2.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.05 | 52 Week High | $77.12 | |||
| Open | $66.80 | 52 Week Low | $49.03 | |||
| Day High | $68.64 | P/E | 43.90 | |||
| Day Low | $66.61 | EPS | $1.54 | |||
| Volume | 13,898,733 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 28.24 +0.99 (3.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.25 | 52 Week High | $37.39 | |||
| Open | $27.60 | 52 Week Low | $28.25 | |||
| Day High | $28.44 | P/E | 17.12 | |||
| Day Low | $27.58 | EPS | $1.65 | |||
| Volume | 59,758,239 | |||||
